Noxafil and Jadenu drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Noxafil (posaconazole) and Jadenu (deferasirox). Common drug interactions include pericardial haemorrhage among females and pancreatitis among males.
The phase IV clinical study analyzes what interactions people have when they take Noxafil and Jadenu. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.
What is Noxafil?
Noxafil has active ingredients of posaconazole. eHealthMe is studying from 5,919 Noxafil users. Check the latest studies of Noxafil.
What is Jadenu?
Jadenu has active ingredients of deferasirox. eHealthMe is studying from 4,176 Jadenu users. Check the latest studies of Jadenu.
13 people who take Noxafil and Jadenu together, and have interactions are studied.
What are the common drug interactions of Noxafil and Jadenu, by gender? *:
female:
- Pericardial haemorrhage (bleeding into the heart)
- Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
- Full blood count decreased
- Lactic acidosis (low ph in body tissues)
- Pericardial effusion (fluid around the heart)
male:
- Pancreatitis (inflammation of pancreas)
- Death
- Immunosuppression
- Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
- Platelet count decreased
- Platelet disorder
What are the common drug interactions of Noxafil and Jadenu, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
- Pancreatitis (inflammation of pancreas)
30-39:
n/a
40-49:
n/a
50-59:
n/a
60+:
- Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
- Death
- Lactic acidosis (low ph in body tissues)
- Pericardial effusion (fluid around the heart)
- Pericardial haemorrhage (bleeding into the heart)
What are the existing conditions these people have? *
- Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 15.38%
- Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 15.38%
- Blood Iron Increased: 1 person, 7.69%
- Aplastic Anemia: 1 person, 7.69%
* Approximation only. Some reports may have incomplete information.
Do you take Noxafil and Jadenu?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Noxafil and Jadenu:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Noxafil:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Jadenu:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Noxafil and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Jadenu and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on posaconazole and deferasirox (the active ingredients of Noxafil and Jadenu, respectively), and Noxafil and Jadenu (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Ertapenem Sodium cause Constipation? - 4 seconds ago
- Could Norplant cause Complications Of Maternal Exposure To Therapeutic Drugs? - 7 seconds ago
- Could Epzicom cause Eating Disorder? - 8 seconds ago
- Could Vitamin B1 cause Hair Loss? - 12 seconds ago
- How effective is Zopiclone for Drowsiness? - 17 seconds ago
- Could Meloxicam cause Breakthrough Pain? - 29 seconds ago
- Could Digoxin cause Swelling? - 32 seconds ago
- Meridia vs. Ephedra, side effect and effectiveness comparison - 32 seconds ago
- Osteoporosis and Ascites - 33 seconds ago
- Drug interactions of Prilosec Otc and Promethazine - 34 seconds ago